On today's episode of This Changes Things hosts Baker Machado and Hope King give a recap of the day's top earnings. In addition, they talk through top tips to ensure your business is a success.
But first, Jason Mayden, CEO and Co-Founder of Super Heroic, joins This Changes Things to discuss how creativity can empower an entire generation. He spent 13 years working for Nike, leading the creation of products for athletes and cultural icons such as Michael Jordan, Carmelo Anthony, and Derek Jeter. At Super Heroic it's his mission to empower children with the power of play through different products.
Plus, everyone has those quirky tendencies, but how do we hone in those attributions and create innovation? Melissa Schilling, Author of "Quirky" and Lydia Dishman, Reporter at Fast Company join This Changes Things to discuss different strategies to becoming a great leader.
Arjan Stephens, President of Nature's Path, discusses the company's origin, how it has evolved today and the interesting product that came from his wedding!
Small business reporter, Gene Marks, joins Cheddar to give analysis on how small businesses are tackling incoming tariffs and how it will affect the consumer.
Babylist CEO Natalie Gordon joins Cheddar to discuss how the website is helping new parents, how to make a registry and how secondhand options are available.
ReturnPro CEO Sender Shamiss to discuss how his company is changing the way we make returns and how Trump's tariffs are affecting the return business. Watch!
Chris Beauchamp, Chief Market Analyst at IG International, joins J.D. Durkin to give analysis on the recent trade truce between the U.S. and China. Watch!
Shan Aggarwal, VP of Corporate and Business Development at Coinbase, discusses the company's acquisitio of Deribit as it heads into the S&P 500. Watch!
Shopping expert Trae Bodge discusses how talks between the U.S. and China is good news for now, but uncertainty remains for back-to-school and the holidays.
Jake Traylor, White House reporter at Politico, joins Cheddar to discuss how Trump is aiming to lower drug prices and how it differs from Biden's approach.
